Information
Address

Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France
Switchboard:

Switchboard

+33 (0)1 42 11 42 11

GUSTAVE ROUSSY
1st cancer center in Europe

© 2006-2015 Gustave Roussy – All rights reserved

Evaluation de la réintroduction d’une immunothérapie anti-PD-1 chez des patients atteints de cancers après arrêt du traitement pour toxicité aigüe

back to job offer list
back to clinical trials

Le 11 juin 2019

CSET 2877

back to job offer list
back to clinical trials

L’immunothérapie fait partie du traitement standard du cancer du poumon dit non à petites cellules à un stade avancé (CPNPC).

Translational Cancer Genomics - Team

back to job offer list
back to clinical trials

Translational Cancer Genomics - Lab members

  • Andrey Yurchenko   
    CRCN INSERM
  • Fatemeh Rajabi   
    PostDoc
  • Irina Groisman   
    CRCN INSERM
  • Sergey Nikolaev   
    DR2 INSERM
  • Jomar Sanglang   
    PhD student
  • Naomi Mfonfu   
    PhD student
  • Yuxuan ZHANG   
    PhD student
  • Mariana Quiro Galondono   
    PosDoc
  • Hanaé Benamira Carrié   
    PosDoc
  • Gueorgui Kratassiouk   
    engineer

Alumni

  • Ivan Valiev   
    bioinformatician
  • Jinxin Wang   

Translational Cancer Genomics - Publications

back to job offer list
back to clinical trials

Translational Cancer Genomics - Major publications

    Translational Cancer Genomics

    back to job offer list
    back to clinical trials

    Translational Cancer Genomics

    The team is supported by ARC foundation grant: "Emerging Leaders in Oncology".

    This team belongs to the UMR 981:"Molecular predictors and new targets in oncology".

    ASCO 2019 - Melanoma: The advantages of targeted dual therapy confirmed at five years

    back to job offer list
    back to clinical trials

    Chicago, 4th June 2019
    ASCO 2019

    ASCO 2019 - Urothelial cancer (bladder and urinary tract): new evidence of the value of immunotherapy

    back to job offer list
    back to clinical trials

    Chicago, 3 June 2019
    ASCO 2019

    Urothelial cancer (bladder and urinary tract)
    New evidence of the value of immunotherapy

    Urothelial cancer, usually developing in the bladder, is common and serious. Its management is complex. It accounts for 90% of bladder cancers. With 12,000 new cases diagnosed each year in France, bladder cancer is the urological cancer encountered most frequently after prostate cancer.

    ASCO 2019 - Larotrectinib, first targeted therapy for childhood solid tumours, shown to be effective

    back to job offer list
    back to clinical trials

    Chicago, 3 june 2019
    ASCO 2019

    Pages